An update on medical Use of Cannabis with new study Results
|
|
- Marian Pitts
- 5 years ago
- Views:
Transcription
1 Disclosures An update on medical Use of Cannabis with new study Results Jacquelyn Bainbridge, PharmD, FCCP, MSCS Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences & Department of Neurology Anschutz Medical Campus Oct. 5, 2018 Bend St. Charles Grand Rounds Dr. Bainbridge has two research grants funded by CDPHE Dr. Bainbridge is involved in one research grant funded by GW Pharmaceuticals/ Greenwich Pharmaceuticals Dr. Bainbridge is involved in one research grant funded by Corbus Pharmaceuticals Learning Objectives Review the pharmacology of cannabis (drug-drug interactions) Identify the disease states which may be treated with cannabis Review current medical literature and studies on the medicinal efficacy of cannabis Describe communication strategies for prospective patients considering or using cannabis treatment Discuss a case study and patient experience with diagnosis, treatment and management Identify the main constituents of cannabis and review the endocannabinoid system AZmarijuana.com
2 Cannabis Contains over 400 compounds Over 100 cannabinoids have been isolated Terpenes are variable, contribute to aroma (limonene, pinene) and serve as a precursor to cannabinoids Cannabinoids & terpenes are found in flowering tops > buds > top leaves > lower leaves > stems stalks Indica and sativa have been cross-bred so no generalizable characteristics Delta- 9 -tetrahydrocannabinol (THC) Major component of cannabis that causes the "high Mechanism of action: Partial CB1 agonist Beneficial effects Helpful in preventing nausea and vomiting due to cancer chemotherapy Appetite promoter Some medical conditions Adverse effects Short Term: Memory loss, loss of time, impaired coordination Altered thinking, panic, delusions & hallucinations, paranoia and psychosis Long term: Addiction (9% overall), altered brain development *, diminished life satisfaction and achievement *, cognitive impairment (lower IQ) *, symptoms of chronic bronchitis, increased risk of chronic psychosis disorders, and poor educational outcome. N Engl J Med 2014; 370: *Effect is strongly associated with initial marijuana use early in adolescence Borgelt LM, Franson KL, Nussbaum AM, Wang GS. Pharmacotherapy Cannabidiol (CBD) Major nonpsychotropic component of cannabis (no high) Precise mechanism of action unknown may be an antagonist Beneficial effects No significant neurologic effects No effects on vital signs or mood Enhance the activity of the endogenous cannabinoid (anandamide) Adverse effects Somnolence, decreased appetite, diarrhea, fatigue, and convulsion May increase risk of infection Industrialized Hemp Colorado Constitution defines Industrialized Hemp as a plant of the genus cannabis and any part of the plant, whether growing or not, containing a delta 9 tetrahydrocannabinol (THC) concentration of no more than 0.3 % on a dry weight basis. Cannabidiol (CBD) Registered industrial hemp farmer with the Colorado Department of Agriculture Marijuana is grown inside with regulated light, temperature, humidity, CO2 and O2 levels to maximized the THC concentration Hemp is grown outdoors to maximize size and yield, less attention is paid to individual plants Sievers is studying medicinal uses for hemp (Denver Post 7/26/18) Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The Pharmacologic and Clinical Effects of Medical Cannabis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2013;33(2): , Epilepsia June ; 55(6): doi: /epi.12631, and Lancet Neurol Mar;15(3): doi: /S (15) Epub 2015 Dec 24.
3 Other Common Cannabinoids Anandamide, 2-AG Naturally-occurring endocannabinoids Dronabinol, nabilone THC molecule, Pharma products Epidiolex CBD extract, Pharma product Sativex THC & CBD extract, Pharma product Rimonabant CB1 receptor inverse agonist, Pharma product HU-210 Spice, synthetic street cannabinoid Most interact with the endocannabinoid system via G-protein-coupled receptors in the body, but not CBD Endogenous Cannabinoid System There are already different types of cannabinoids in our body that stimulate CB1 and CB2 receptor function Located in different parts of the body (i.e. brain, organs, connective tissue, glands, and immune cells) Each tissue has different tasks within the system to maintain homeostasis (balance) Examples of effects: Increased appetite Decreased nausea and vomiting Borgelt LM, Franson KL, Nussbaum AM, Wang GS. Pharmacotherapy to the endocannabinoid system Accessed 3/2/15 Frontiers in Pharmacology 2014;5:Article 37 Regulatory Effect of Cannabinoids at the CB1 Receptor 1. Inhibition of adenylyl cyclase activity 2. Alter second messenger systems so CA++ influx is inhibited Neuromodulation by anandamide is particularly relevant to modulation of GLU (shown), Ach, GABA, DA, NE Pertwee RG. Br J Pharmacology Functional effects of anandamide at CB1 receptors in the CNS Structure Anandamide Regulates Resultant effect Basal ganglia Modulate DA & GABA, motor activity Slowed reaction time Hypothalamus Appetite (2-AG) Stimulate DA & inhibit NE Appetite Inhibition of prolactin, enhances ACTH Amygdala Emotions, fear, anxiety Anxiety stimulation, reduction, & sedation Nucleus accumbens Motivation (2-AG) Engages reward pathway Hippocampus Inhibit release Ach, short term memory Inhibit release GLU, long term memory Impaired short term (working) memory Impaired long term memory consolidation Cerebellum Inhibit GLU, motor coordination Impaired coordination, balance Brain stem Modulates info transfer between brain & spinal cord Anti-nausea effects Hippocampus, TL, forebrain Inhibit GLU & neuronal excitability Increased seizure threshold
4 Functional effects of anandamide at CB1 & CB2 receptors Structure Anandamide regulates Resultant effect Spinal cord Inhibit GLU & info transfer between body & brain Decreased pain sensitivity Parasympathetic Inhibit Ach release, HR regulation, urination regulation HR stimulation, sometimes inhibits urination system Sympathetic system Inhibit NE release, HR regulation, blood vessel constriction Delayed reduction in HR and blood pressure Neuronal cells Inhibition GLU-induced excitotoxicity Neuroprotective effect to prevent cell injury Adipose tissue Stimulates lipogenesis Increased adiposity, insulin resistance Reproductive tissue Reduces testosterone, luteinizing hormone Reduced fertility, altered menstrual cycle Skin Reduces histamine Anti-pruritic effect General Role in relaxing, eating, sleeping, forgetting protecting Provide relief from stress, reduction of injury General Inhibits immune B lymphocytes, natural killer cells Anti-inflammatory activity Cannabis Activity At CB1 Receptors Structure THC effect CBD effect Neocortex Altered thinking, judgement Delayed onset time to intoxication with THC Basal ganglia Slowed reaction time Reduced psychomotor abnormalities from THC Hypothalamus appetite 1992 No to little effect on appetite Amygdala Panic, paranoia Decrease THC induced anxiety Nucleus accumbens Euphoria Attenuated THC induced euphoria Hippocampus Impaired memory Attenuated THC induced memory effects Cerebellum Impaired coordination Reduced coordination abnormalities from THC Brain stem Anti-nausea effects 1985 Hippocampus, forebrain Anti-epileptic effects? Anti-epileptic effects for certain populations Spinal cord Altered pain sensitivity TRPV reduction in pain 1996 Dose-response effects of CBD not established low dose < 300 mg inconsistent effects typical response can be seen at 600mg Study 1: GWPCARE4 Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomized, double-blind, placebo-controlled phase 3 trial Randomized, placebo-controlled trial. N = 171 Add-on to an anticonvulsant regimen for drop seizures in LGS refractory patients Patients age 2-55 years old What s Refactory? > 2 AED meds and > 2 drop seizures per week Doses: 20 mg/kg of cannabidiol or placebo (in addition to current therapy) Primary outcome: reduction in drop seizures. Secondary outcome: adverse events Followed for 14 weeks.
5 GWPCARE4 Results and Outcomes GWPCARE4 Take-home points Primary: drop seizure frequency percentage Treatment group: 43.9% (IQR to -1.9) Control group: 21.8% (IQR to 1.7) Secondary: adverse events Common (>10%): vomiting, diarrhea, decreased appetite, pyrexia, and somnolence. Serious: increased ALT, AST, and y-glutamyltransferase Cannabidiol 20 mg/kg was an effective treatment for reducing seizure rate in non-elderly LGS patients. Number needed to treat: 5 patients Generally well tolerated Effect of Cannabinidiol on Drop Seizures in the Lennox- Gastaut Syndrome Very similar to GWPCARE4 in structure: Multicenter, placebo-controlled trial 14 week treatment period 2-55 year old patients Primary outcome: percentage reduction in seizure rate from baseline. Secondary outcome: side effects Same exclusion criteria. Key differences: Patients with 2 or more drop seizures a week during a 4 week baseline period. 3 groups: 20 mg/kg, 10 mg/kg, or matching placebo in two divided doses N= 225
6 Results Primary Outcome: 20 mg/kg: 41.9% 10 mg/kg: 37.2% Placebo: 17.2% Comparisons of Primary Outcome between groups: 20 mg/kg to placebo: 21.6 (95% CI, 6.7 to 34.8; p=.005) 10 mg/kg to placebo: 19.2 (95% CI, 7.7 to 31.2; p=.002) NNT: 4 Secondary Outcome: A lot of the same side effects seen with GWPCARE4. Big picture: 10 mg/kg had less side effects than 20 mg/kg Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome Cannabidiol in Dravet syndrome Double-blind, placebo-controlled trial of 120 patients. Patients 2-18 years old with refractory seizures. 2 arms: 20 mg/kg of cannabidiol (twice daily in equal doses) vs. placebo as an add-on to standard AED regimens. Patients inadequately controlled on >1 AED with >4 seizures during the baseline period. Results Treatment Group: (-38.9% IQR to -4.8) Placebo Group: (-13.3% IQR to 20.2) Other: Interactions with Valproate: increased AST and ALT, but no effect on serum levels
7 Dosing and administration consensus Starting dose is recommended at 2.5 mg/kg twice daily, with titration to 5 mg/kg twice daily as a maintenance dose after one week. Cannabidiol (Epidiolex ) First FDA approved cannabinoid prescription drug Treatment of Lennox-Gastaut syndrome and Dravet syndrome Oral solution 100 mg/ml Starting dosage 2.5 mg/kg twice daily; maximum 10 mg/kg twice daily Drug Interactions Use with strong CYP3A4 or CYP2C19 inducers may decrease cannabidiol plasma concentration Potential enzyme activity inhibition; reduce dose of substrates of UGT1A9 (Propofol, fenofibrate, diflunisal), UGT2B7 (Gemfibrozil, lamotrigine, morphine, lorazepam), CYP2C8 (Phenytoin), and CYP2C9 (Phenytoin) when used with Epidiolex Potential induction and inhibition of enzyme activity; adjust dosage of substrates CYP1A2 (theophylline, caffeine) and CYP2B6 (bupropion, efavirenz) when used with Epidiolex Cannabidiol (Epidiolex ) Cannabidiol (Epidiolex ) Drug Drug Interactions Effect of Epidiolex on the other drugs: UGT1A9 diflunisal, propofol, fenofibrate UGT2B7 gemfibrozil. Lamotrigine, morphine, lorazepam CYP1A2 theophylline, caffeine, clozapine CYP2B6 bupropion, efavirenz CYP2C8 phenytoin CYP2C9 Carvedilol, celecoxib, glipizide, ibuprofen, irbesartan, losartan CYP2C19 Omeprazole, phenobarbital, phenytoin, diazepam Increases plasma concentration of drug Drug Drug Interactions Effect of other drugs on Epidiolex: Metabolized by 3A4 and 2C19 so Coadministration with moderate to strong inhibitors will increase Epidiolex concentration 3A4 inhibitors diltiazem, verapamil, ketoconazole, itraconazole, erythromycin 2C19 Inhibitors Fluvoxamine, isoniazid (INH), ritonavir Coadministration with strong inducers will decrease Epidiolex concentration 3A4 inducers Carbamazepine, St. John's wort, phenobarbital, phenytoin, rifampin 2C19 inducers Carbamazepine, phenytoin, rifampin
8 Drug Interactions *Epidiolex + Clobazam Cannabidiol (Epidiolex ) Produces 3-fold increase in plasma concentrations of active metabolite of clobazam (substrate of CYP2C19) Epidiolex + Valproate Concomitant use increases the incidence of liver enzyme elevation * Epidiolex + Rufinamide or topiramate Increased serum concentration of rufinamide or topiramate *Gaston TE et al., Epilepsia 2017 Sept;58(9): Warnings Cannabidiol (Epidiolex ) Epidiolex causes dose-related elevations of ALT and AST In 2/3 cases, discontinuation or reduction of Epidiolex resolved transaminase elevations In 1/3 cases, elevations resolved without dose reduction of Epidiolex Dose adjustment recommended in patients with moderate (Child-Pugh B) or severe (Child- Pugh C) hepatic impairment. Slower dose titration may be necessary Increased the incidence of liver enzyme elevations with valproate administration Epidiolex meets highest standards for safety and quality, unlike other medical marijuana products Expected to be made available in specialty pharmacies in Fall 2018 DEA scheduled V THC Dosing Is Known; But Not Known For Other CBs Typical effective dosing of inhaled THC Low dose < 7 mg Medium dose = 7 18 mg High dose > 18 mg Known tolerance to THC down regulation of CB1 receptors, and G- protein activation High probability of tolerance with chronic use, and low with intermittent Chronic = daily for a week, intermittent = weekly Case Study 1 CB is a 10 year old male who has a diagnosis of Dravet Syndrome. CB is currently experiencing 4 seizures per day on average. CB has been on multiple anti-seizure medications including topiramate and phenytoin with no decrease in seizures. Currently he has been placed on clobazam and dose escalated to 20 mg orally twice daily. Two weeks ago his parents entered him into a clinical trial with Epidiolex. CB reports ataxia and sedation to the point of not being able to get out of bed. What is the source of his CNS toxicity? L Zuurman, et al. Br J Clinical Pharmacology. 2008
9 Case Study 1 Follow Up Epidiolex + Clobazam Produces 3-fold increase in plasma concentrations of active metabolite of clobazam (substrate of CYP2C19) The dose of clobazam should be decreased by 50 percent and re-evaluated Without knowing his previous regimen if he presented with LFTs that are elevated 6 times the ULN. Which antiseizure drug would you suspect to be the most likely to cause this in combination with Epidiolex? MEDICAL USES OF CANNABIS Evidence from the National Academies: Health Effects of Cannabis A provider asks We never learned about cannabis in medical school, what can you tell me about the diseases that medical marijuana has been approved for? Number of States with Various Approved Medical Conditions States cannabis legal status Medical: 29 states & D.C. Recreational: AK, CA, CO, D.C., MA, ME, NV, OR, WA Alzheimer s disease (7) Epilepsy/seizures (24) Nausea (19) ALS (9) Glaucoma (21) Pain (20) Arthritis (3) Hepatitis C (10) Parkinson s disease (5) Cachexia (21) HIV/AIDS (24) PTSD (6) Cancer (25) Multiple sclerosis (21) *decriminalization laws Crohn s/gi disorders (16) Muscle spasticity (22) By Lokal_Profil, CC BY-SA 2.5,
10 Approved medical conditions Approved medical conditions National Academies of Sciences, Engineering, and Medicine The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press doi: /24625 National Academies of Sciences, Engineering, and Medicine The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press. doi: / Approved Medical Conditions Current legislation is misleading Cannabis may alleviate symptoms but not actually treat the disease MS, cancer, HIV/AIDS, hepatitis C, Crohn s and Alzheimer s disease Do our patients/consumers know the difference? RISKS ASSOCIATED WITH CANNABIS
11 Lifetime Addiction Risk with Use Brain Development in Adolescence % MJ addiction risk in teens Limbic region Immediate rewards Impulsive behavior Cortex Long term gain Thoughtful behavior accessed 5/28/2013 Hall and Degenhardt. Lancet Strahny A. CBHSQ Report ) The Reward Pathway Study comparing the acute effects of inhaled cannabis in male adolescents (n = 20; years old) and adults (n = 20; years old). Participants completed two test sessions that lasted for 80 minutes each and was separated by at least 7 days. NIDA ( Inhaled medicinal grade Bedrobinol (THC 12.0%) or placebo (THC <0.3%) via a volcanic medic vaporizer. Weight based dosing; 0.89 mg/kg -1 of cannabis ~8.0 mg of THC for an person weighing 75 kg Translational psychiatry (2016) 6, e961;doi: /tp ; published online 29 November 2016
12 Acute Effects Adolescents Felt less stoned Dry mouth No difference in alertness or anxiety Fewer psychotomimetic symptoms Impaired response inhibition Lacked satiety and wanted more cannabis Translational psychiatry (2016) 6, e961;doi: /tp ; published online 29 November 2016 Adults More anxious Increased dry mouth Less alert Greater cognitive impairment Longer response times Spatial working memory tasks Showed satiety and did not want more cannabis No difference in verbal IQ, Beck anxiety and depression inventory, short version of impulsive behavior scale (SUPPS-P), Schizotypal personality questionnaire and both had increased heart rate A prospective longitudinal study investigating the correlation between persistent cannabis use over 20 years in a birth cohort of 1,037 individuals. Also observed the effect of cannabis cessation and the restoration of neurophyschological function for adolescents who were former persistent cannabis users. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences. 2012;109(40). doi: /pnas Effect on Neuropsychological Functioning Persistent cannabis users show neuropsychological decline from childhood to midlife Prospective study of 1,037 individuals followed from birth (1972/1973) to 38 years of age Within-person IQs : Never used Used, never regularly Used regularly Impairment of learning, memory, and executive functions Older Adult Data Data suggest that substance abuse in the elderly is rising Multiple reasons that it is initiated later in life including coping with loss Brain It continues to change even in elderly years There is scant data on how drugs of abuse, including marijuana, interact with these continuing brain changes From Emergency Department (ED) mentions of illicit drug use have risen among patients 55+ Marijuana; 300 to 1700 respectively ( ) Meier MH, et al. Proc Natl Acad Sci Dowling GJ, Weiss SRB, Condon TP. Drugs of Abuse and the Aging Brain. Neuropsychopharmacology. 2007;33(2):
13 Cannabis Drug Interactions Further Dosing Considerations THC substrate of CYP3A4 & 2C9 CBD substrate of CYP3A4 & 2C19 Possible drug interactions sedation, ataxia: CNS depressants, anticholinergics heart rate: sympathomimetics effects of: hexobarbital, hydrocortisone, clozapine, phenytoin, warfarin effects of: propofol, indinavir, theophylline Horn JR, Pharmacy Times 2014 Drug-Drug interactions CBD and AEDs Study looked at effect of CBD oil (Epidiolex) on serum concentrations of AEDs N = 81: 39 adults/42 pediatric patients; initiated at 5 mg/kg/day, titrated up to efficacy, max dose of 50 mg/kg/day Significant increase in serum levels of topiramate, rufinamide, desmethylclobazam (active metabolite of clobazam), in all patients. Drug-Drug interactions CBD and AEDs Decrease in levels of clobazam as CBD increased No significant interactions between CBD and levetiracetam, lacosamide, perampanel Clinical significance: patients on clobazam or valproate, with adjunctive CBD use, experienced increased sedation that required dose adjustments Significant increase in serum levels of zonisamide and eslicarbazepine, only in adults AES Abstract 2.208: Gaston T, Liu Y, Cutter G, et al. Drug interactions between pharmaceutical grade cannabidiol (CBD) oil and commonly used anti-epileptic drugs (AEDs). Szaflarski J, et al. How does cannabidiol interaction with antiepileptic drugs? Neurology Reviews. January AES Abstract 2.208: Gaston T, Liu Y, Cutter G, et al. Drug interactions between pharmaceutical grade cannabidiol (CBD) oil and commonly used anti-epileptic drugs (AEDs). Szaflarski J, et al. How does cannabidiol interaction with antiepileptic drugs? Neurology Reviews. January 2017.
14 Drug-Drug interactions - CBD and Clobazam (CLB) Study looked at CBD and clobazam use in 13 pediatric patients Initiated at 5mg/kg/day and titrated up to goal dose of 25mg/kg/day Measured serum concentrations of clobazam and desmethylclobazam at baseline, 4 weeks, and 8 weeks Mean increase in CLB levels: 60% Mean increase in nclb levels: 500% Nine subjects saw >50% decrease in seizure frequency Ten subjects saw increase in sedative side effects, which was alleviated with CLB dose reductions THC Drug-Drug Interactions THC is metabolized by CYP3A4 and 2C9 Valproate inhibition of CYP2C9 can potentiate psychotropic effects of THC through a decrease in THC plasma clearance In vitro evidence shows THC is an inhibitor of CYP2C9, 2C19, 3A4 and 1A2 Evidence that THC increases phenytoin concentrations through CYP2C9 inhibition Has potential drug drug interactions with CYP3A4 inhibitors and inducers Geffrey AL, Pollack S, Bruno P, Thiele E. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015; 56(8): Anderson, G.D. & Chan, LN. Clin Pharmacokinet (2016) 55: doi: /s Inhaled Cannabis vs. Edibles How is Cannabis Consumed?
15 Cannabis-Infused Creams, Lotions and Oils Transdermal Patches Lipophilic delivery vehicles plausible due to high lipophilicity of THC CB receptors innervate: Epidermal homeostasis Pain sensation Skin inflammation Development, maintenance, and function of hair follicles and sebaceous glands Patch or gel designed to be absorbed through skin to blood stream Reservoir & occlusion provides constant & complete dosing Increase bioavailability of cannabinoids by skipping first-pass metabolism MJ Caterina ACS Chem Neurosci 2014 Images from: Communication Strategies Facilitating Physician and Patient Communication about Cannabis Current problem: Inadequate information that is needed to help providers determine whether cannabis should be considered as a treatment option for their patients Cannabis stigma Solutions: increased awareness Conferences Clinical trials Primary Literature Presentations
16 Important Considerations- Provider Perspectives When did the patient start using cannabis? How is the patient using cannabis? (smoking, vaporizing, eating, oils, etc.) How often does the patient use cannabis? What medications and over the counter medications is the patient taking? Overall expectations- what benefit does the patient expect from the use of cannabis? Important Considerations- Patient Perspectives What studies have been done that use cannabis to alleviate symptoms associated with my patients condition? Are there any side effects or potential complications I should be aware of? Will cannabis have interactions with any of the medications I am currently taking? What are the different forms of cannabis available, and what healthcare costs can I expect? Willie Nelson Grows Cannabis Empire With New Line of CBD Oil Products Questions? Amie, Biggie, Gucci
17 Which AED has a major drug-drug interaction with CBD (Epidiolex)? Levetiracetam Lacosamide Clobazam Perampanel Which AED has a major drug-drug interaction with CBD (Epidiolex)? Levetiracetam Lacosamide Clobazam ANSWER Perampanel Which of the following is a condition that has evidence backing the use of cannabis for treatment? Irritable bowel syndrome Nausea and vomiting related to chemotherapy Achieving abstinence in the use of addictive substances Parkinson s or levodopa related muscle movements Which of the following is a condition that has evidence backing the use of cannabis for treatment? Irritable bowel syndrome Nausea and vomiting related to chemotherapy ANSWER Achieving abstinence in the use of addictive substances Parkinson s or levodopa related muscle movements
18 Which is false about the use of cannabis edible preparations? Edible cannabis has the fastest onset of action, taking 5-10 minutes The duration of effect is longer than smoking or vaporizing cannabis Edibles contain more 11-OH-THC, which is more potent than standard THC Production of edibles requires a lower temperature than vaporizing or smoking cannabis Which is false about the use of cannabis edible preparations? Edible cannabis has the fastest onset of action, taking 5-10 minutes ANSWER The duration of effect is longer than smoking or vaporizing cannabis Edibles contain more 11-OH-THC, which is more potent than standard THC Production of edibles requires a lower temperature than vaporizing or smoking cannabis What is the CBD:THC ratio or THC concentration used in the FDA-approved CBD preparation for Epidiolex? 30:1 15:1 10:1 Up to 1% THC Up to 0.15% THC This preparation does not contain THC What is the CBD:THC ratio or THC concentration used in the FDA-approved CBD preparation for Epidiolex? 30:1 15:1 10:1 Up to 1% THC Up to 0.15% THC ANSWER This preparation does not contain THC
19 According to the Colorado Constitution, what is the maximum THC concentration that is allowed in industrial hemp on a dry weight basis? 0.01% 10% 12% 0.3% 22% According to the Colorado Constitution, what is the maximum THC concentration that is allowed in industrial hemp on a dry weight basis? 0.01% 10% 12% 0.3% ANSWER 22% Current Clinical Trials at The University of Colorado Anschutz Medical Campus A study of tolerability and efficacy of cannabidiol on tremor In Parkinson s disease Efficacy and safety of cannabidiol as add on therapy in patients with tuberous sclerosis complex who experience inadequately controlled seizures CURRENT RESEARCH CDPHE and other funding A phase 3, double-blind, randomized, placebo-controlled multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of Lenabasum in systemic sclerosis
20 A Double-Blind, Placebo-Controlled Crossover Study Comparing the Analgesic Efficacy of Cannabis versus Oxycodone; Questions we are trying to answer Pain Control Is cannabis effective at relieving chronic spine pain? Does it increase the threshold for perceiving pain? How does it compare to an opioid (pain medicine) for pain? Study Design Subjects come in for 3 separate 4-hour study visits Vaporized Cannabis + Placebo pill Vaporized Placebo + Oxycodone pill Vaporized Placebo + Placebo pill Side Effects How do the side effects of cannabis compare to the side effects of the opioid (pain medicine)? Outcomes (What are we measuring) Pain control Patient reported pain Pain sensitivity with experimentally induced pain Side effects Mood changes (feeling high, confused, paranoid, etc...) Cognitive changes (memory, attention, concentration, etc...)
Epidiolex (cannabidiol) NEW PRODUCT SLIDESHOW
Epidiolex (cannabidiol) NEW PRODUCT SLIDESHOW Introduction Brand name: Epidiolex Generic name: Cannabidiol Pharmacological class: Cannabinoid Strength and Formulation: 100mg/mL; oral soln; strawberry-flavored;
More informationInvestigational Pharmacy Cannabidiol treatment in Epilepsy
Jon Beck BS Pharm D Coordinator Investigational Pharmacy Disclosure I have no relevant financial relationships with a Commercial Provider Nebraska Medicine Omaha, NE Investigational Pharmacy Cannabidiol
More informationMedical Cannabis. Kari L. Franson, PharmD, PhD, BCPP Associate Dean and Associate Professor Department of Clinical Pharmacy
Medical Cannabis Kari L. Franson, PharmD, PhD, BCPP Associate Dean and Associate Professor Department of Clinical Pharmacy Objectives Identify the main constituents of cannabis Review the endocannabinoid
More informationCannabis. Member of the Cannabaceae family of flowering plants (along with hops) Cannabis sativa (v. sativa, indica, afghanica, ruderalis)
Member of the Cannabaceae family of flowering plants (along with hops) sativa (v. sativa, indica, afghanica, ruderalis) Only females flowers contain high concentrations of psychoactive oils (cannabinoids)
More informationMedical Cannabis. Kari L. Franson, PharmD, PhD, BCPP Associate Dean for Professional Education
Medical Cannabis Kari L. Franson, PharmD, PhD, BCPP Associate Dean for Professional Education At the end of this activity, participants should be able to: 1) Identify the contents in cannabis that effect
More informationResearch on Cannabis and PD: Is there any evidence?
Research on Cannabis and PD: Is there any evidence? Benzi M. Kluger, MD, MS Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver DISCLOSURES
More informationCannabis in the treatment of Autism:
Cannabis in the treatment of Autism: Are we ready? Deb Karhson, PhD and Lawrence Fung, MD, PhD Cannabis Anecdotal Data: Comparing Epilepsy and Autism+ Science of Cannabinoids: Endocannabinoid System Receptor
More informationMedical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center. Disclosure.
Medical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center Controversies in Pain Management Conference Johnson City, TN November 13, 2015 Disclosure
More informationMarijuana and Adolescents: Truth and Consequences. Disclosure Statement OBJECTIVES. Secondary Objectives. State of Marijuana in US
Marijuana and Adolescents: Truth and Consequences Clinical Advances in Pediatrics Symposium Children s Mercy Park September 28, 2017 Disclosure Statement I have no actual or potential conflict of interest
More informationThe Effects known & unknown of Marijuana in Older Adults. Danielle Fixen, PharmD, BCGP, BCPS University of Colorado School of Pharmacy
The Effects known & unknown of Marijuana in Older Adults Danielle Fixen, PharmD, BCGP, BCPS University of Colorado School of Pharmacy Learning Objectives 1. Review various dosing strategies for medical
More informationFederal Law: Marijuana
Federal Law: Marijuana Marijuana is a Schedule I drug under Federal Controlled Substances Act Makes possession, usage, purchase, sale, and/or cultivation of marijuana illegal at the federal level May not
More informationMedical Cannabis MATT WEBSTER DO, MS
Medical Cannabis MATT WEBSTER DO, MS Cannabis Sativa One of the oldest used drugs and medicinal remedies Most commonly abused illicit drug in the US There has been increasing access for medicinal MJ use
More informationCurious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD
Curious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD Speaker Disclosures We have/had no financial relationships with any commercial interests
More informationI would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people
I would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people Introduction to the Cannabinoid System And Medical Use Dr Alia Norman Radiation Oncologist Cannabinoid
More informationBudding Therapies: Medical Cannabis and its Uses
Budding Therapies: Medical Cannabis and its Uses MARIAH CADAVOS, PHARMD & VIVIAN NGUYEN, PHARMD PGY1 PHARMACY PRACTICE RESIDENTS FEBRUARY 10, 2019 1 Disclosures & Disclaimer Both presenters have nothing
More informationMarijuana and cannabinoids
Psych 181: Dr. Anagnostaras Lec 10: Marijuana Marijuana and cannabinoids Cannabis sativa, hemp One of earliest non-food plants cultivated fiber for rope, seeds for oil and birdseed 1st archaeological evidence
More informationMedical Marijuana Update Chris Belletieri, DO
Dr. Belletieri has provided no disclosures. Graduated PCOM in 1996 In private practice since 1999 Board Certified in FP since 1999 Program Director of FP residency at Lower Bucks Hospital in Bristol, PA
More informationCannabidiol as a potential treatment for anxiety disorders. Esther Blessing, MD PhD
Cannabidiol as a potential treatment for anxiety disorders Esther Blessing, MD PhD Overview History and of cannabidiol (CBD) and cannabis Safety and tolerability of CBD CBD pharmacology Clinical need for
More information9/28/2015. Support. R01CA A1 Intervening with smoking parents of inpatients to reduce
Medical marijuana and the impact of marijuana policy on children Karen M. Wilson, MD, MPH, FAAP Associate Professor of Pediatrics Section Head, Pediatric Hospital Medicine University of Colorado School
More informationCANNABIS LEGALIZATION: SUPPORT MATERIAL FOR MANITOBA PHYSICIANS
CANNABIS LEGALIZATION: SUPPORT MATERIAL FOR MANITOBA PHYSICIANS 1. GENERAL INFORMATION Cannabis 101 What is cannabis? Cannabis is a product derived from the Cannabis sativa plant. Cannabis contains hundreds
More informationCannabinoids (CB): Outline. CB: Epidemiology. CB: Categorization. CB: Pharmacodynamics. Part #1: Cannabinoid (CB) Primer.
Cannabinoids (CB): Outline 1 2 PART #1: CB Primer Epidemiology Categorization: Endogenous vs. exogenous Natural vs. synthetic Pharmacodynamics (PD) Pharmacokinetics (PK) CB receptor system CNS regional
More information9/13/2017. Marijuana and the Brain Matthew Wong, MD Assistant Professor, Department of Neurology, Epilepsy Section. Disclosures.
Marijuana and the Brain Matthew Wong, MD Assistant Professor, Department of Neurology, Epilepsy Section Disclosures Site principal investigator of studies of cannabidiol(epidiolex) in the treatment of
More informationCANNABIS FOR THE RHEUMATOLOGIST
CANNABIS FOR THE RHEUMATOLOGIST Dr Jagtar Singh Nijjar NIHR Clinical Lecturer in Rheumatology Disclosures None 1 Overview The history of cannabis use Anecdotal use of cannabis in chronic pain The biology
More informationAcknowledgements: What it is What it s not. Cannabis Evidence Series. Evidence-informed decision-making
Cannabis Evidence Series What it is What it s not Acknowledgements: The evidence presented is from the Cannabis evidence series authored by the HTA unit at the University of Calgary and from Rapid response
More informationADVANCED CLINICAL CANNABINOID PROVIDER EXAM ACCP
ADVANCED CLINICAL CANNABINOID PROVIDER EXAM ACCP Page 1 1. In what year did the possession and transfer of cannabis for recreational use become illegal in the United States? A. 1937 B. 1941 C. 1933 2.
More informationMedical vs Recreational Use of Cannabis. 11 th December 2017
1 Medical vs Recreational Use of Cannabis 11 th December 2017 2 Defining Cannabis and Chemical Constituents Cannabis is a plant species. Two main Cannabis sub-species are Cannabis Sativa and Cannabis Indica.
More informationCannabinoids and Epilepsy. Michael Ciliberto, MD University of Iowa Stead Family Department of Pediatrics
Cannabinoids and Epilepsy Michael Ciliberto, MD University of Iowa Stead Family Department of Pediatrics Cannabinoids Cannabinoids= terpenophenolic compounds (give a scent) >80 in Cannabis sativa Cannabidiol
More informationLearning Objectives 1/8/2019. Therapeutic Potential of the Marijuana-Derived Cannabinoids THC and CBD. Disclosures. Outline. Take home messages
Therapeutic Potential of the Marijuana-Derived Cannabinoids THC and CBD CECILIA HILLARD, PHD DEPARTMENT OF PHARMACOLOGY NEUROSCIENCE RESEARCH CENTER Disclosures Member of the Scientific Advisory Board
More informationMedical Marijuana. 1. is a plant species, variety known as hemp. 3. Tetrahydrocannabinol is an aromatic with low water solubility.
Medical Marijuana Questions from Part 1: 1. is a plant species, variety known as hemp. a. Cannabis sativa Linnaeus b. Cannabis sativa c. Cannabis indica d. Cannabis Lemark 2. The major psychoactive compound
More informationMedical Marijuana: The Move to Schedule II
Medical Marijuana: The Move to Schedule II David Deitz, MD, PhD David Deitz & Associates Today s discussion Does medical marijuana actually treat anything? What are the workplace issues? What are the interactions
More informationA look at Marijuana in 2014
A look at Marijuana in 2014 Paul Snyder MA., LADC Overview and Objectives Discuss the mental and physical effects of marijuana use Describe the criteria for Cannabis use disorder according to the DSM 5
More informationSubject: Cannabidiol (Epidiolex )
09-J3000-08 Original Effective Date: 09/15/18 Reviewed: 08/08/18 Revised: 00/00/00 Next Review: 04/10/19 Subject: Cannabidiol (Epidiolex ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationCannabis for Drug Resistant Epilepsy
Cannabis for Drug Resistant Epilepsy MILA SORIN, MD PEDIATRIC NEUROLOGY APRIL 20, 2018 Introduction -Although more than 20 prescription anti-epileptic drugs (AEDs) are available, they prove to be ineffective
More informationCannabinoids and Mental Health
Cannabinoids and Mental Health https://upload.wikimedia.org/wikipedia/commons Karen M. Lounsbury, PhD Professor of Pharmacology 802-656-3231, Karen.lounsbury@uvm.edu Objectives Describe the underlying
More informationCANNABIDIOL (CBD) THE BE ALL END ALL?
CANNABIDIOL (CBD) THE BE ALL END ALL? John Schaeffer, DO PMG neurology specialists Clinical associate professor Department of neurology University of Washington school of medicine CANNABIS BRIEF HISTORY
More informationMedical Marijuana Consent Form
Medical Marijuana Consent Form A qualified physician may not delegate the responsibility of obtaining written informed consent to another person. The qualified patient or the patient s parent or legal
More informationSteven G. Kinsey, PhD Associate Professor, Department of Psychology West Virginia University
Steven G. Kinsey, PhD Associate Professor, Department of Psychology West Virginia University sgkinsey@mail.wvu.edu Any opinions expressed are my own and do not reflect any official position of WVU beanpot.co
More informationUSING ALTERNATIVE MEDICATION: MEDICAL CANNABIS (MARIJUANA)--BENEFITS AND HARMFUL EFFECTS JENNIFER KAPUR, PHARM.D. MARCH 1, 2016
USING ALTERNATIVE MEDICATION: MEDICAL CANNABIS (MARIJUANA)--BENEFITS AND HARMFUL EFFECTS JENNIFER KAPUR, PHARM.D. MARCH 1, 2016 OBJECTIVES Compare and contrast federal law and state laws regarding marijuana
More informationJames McCormack BSc (Pharm), PharmD Professor Faculty of Pharmaceutical Sciences University of British Columbia Vancouver, BC, Canada
James McCormack BSc (Pharm), PharmD Professor Faculty of Pharmaceutical Sciences University of British Columbia Vancouver, BC, Canada My Agenda Discuss the best available evidence Put the evidence into
More informationMEDICAL MARIJUANA: WHAT S THE EVIDENCE?
MEDICAL MARIJUANA: WHAT S THE EVIDENCE? L A U R A A. M A R K L E Y, M D B O A R D - C E R T I F I E D I N P E D I A T R I C S / G E N E R A L P S Y C H I A T R Y / C H I L D & A D O L E S C E N T P S Y
More informationOutcome. Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C
Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana Connie J. Cerilli, APRN, FNP-C Outcome Participants will be able to list 3 approved medical conditions Participants will
More informationEducating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C
Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana Connie J. Cerilli, APRN, FNP-C Outcome Participants will be able to list 3 approved medical conditions Participants will
More informationMedical Marijuana. Navigating Medical Marijuana in Workers Compensation
Medical Marijuana Navigating Medical Marijuana in Workers Compensation Agenda Federal and State Laws Public Health Adverse Effects & Concerns Clinical Use Implications for Employers Implications for Workers
More informationThe Shifting Federal Regulation of Cannabis Products
The Durham Bar 2019 CLE Program The Shifting Federal Regulation of Cannabis Products Erica M. Jackson, FDA Partner K&L Gates February 6, 2019 Copyright 2018 by K&L Gates LLP. All rights reserved. OVERVIEW
More informationWhat to do when cannabis gets admitted
What to do when cannabis gets admitted I have nothing to disclose and no conflicts of interest or funding sources I will be discussing unapproved drugs and unapproved uses for drugs Kari L. Franson, PharmD,
More informationTownhall: Benefits, Risks and Applications of Medical Cannabis
Townhall: Benefits, Risks and Applications of Medical Cannabis Laura M. Borgelt, PharmD, FCCP, BCPS Professor and Associate Dean University of Colorado Skaggs School of Pharmacy Annual Meeting & Exposition
More informationHistory Of Medical Cannabis
History Of Medical Cannabis Historical and archaeological evidence of widespread use in ancient times as medicine, food, textiles & for sacraments, rituals Possibly first domesticated crop Introduction
More informationAct 16 and Medical Cannabis in Pennsylvania
Act 16 and Medical Cannabis in Pennsylvania Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA, FESC, FCPP Associate Provost and Professor of Emergency Medicine Director, Institute of Emerging Health
More informationMedicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer
Medicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer Medicinal cannabis Substantial public interest Legalised by the Qld Government Guidance
More informationTHE COMPLETE CBD GUIDE
THE COMPLETE CBD GUIDE WHAT IS CBD (CANNABIDIOL)? 2 WHERE DOES CBD COME FROM? 3 HOW DOES CBD WORK IN THE BODY? 4 HOW MUCH CBD DO I TAKE? 5-6 CBD OIL VS. HEMP OIL 7 CBD NOT THC 8 THE BENEFITS OF CBD 9 PETS
More informationCBD and Your Health.
CBD and Your Health. Cannabidiol (CBD) is a molecule found in plant species such as agricultural (or industrial) hemp, and Echinacea. CBD is one of at least 489 distinct compounds within hemp: it is clear
More informationDisclosure. Learning Objectives
Linda D. Leary, M.D. Associate Clinical Professor of Pediatrics & Neurology South Texas Comprehensive Epilepsy Center UT Health Science Center San Antonio Disclosure Linda D. Leary, M.D. discloses the
More informationPennsylvania House of Representatives. Joint Health and Judiciary Committee Hearing. Medical Cannabis - Health Care Forum
Pennsylvania House of Representatives Joint Health and Judiciary Committee Hearing Medical Cannabis - Health Care Forum Tuesday, March 24, 2015 Philadelphia, Pennsylvania Testimony offered by: David J.
More information4/15/2019. US States with Marijuana Laws in Have ACOG and SMFM taken notice? THE EFFECTS OF MARIJUANA USE ON PREGNANCY AND LACTATION
THE EFFECTS OF MARIJUANA USE ON PREGNANCY AND LACTATION Susan R Davidson, MD Maternal Fetal Medicine Department of Ob/Gyn St. Mary s Hospital Madison, WI SSM Health I HAVE NO FINANCIAL DISCLOSURES TO REPORT
More informationMD GUIDE TO USING MEDICAL CANNABIS
Natural Remedy MD GUIDE TO USING MEDICAL CANNABIS The leaves and flowers of the Cannabis plant are consumed in several forms: dried flower buds or various types of concentrated, loose, or pressed resin
More informationWeeding Through the Science of Cannabis. Ryan Vandrey, PhD
Weeding Through the Science of Cannabis Ryan Vandrey, PhD What is Cannabis? Basic Plant Information Cannabis is a genus of plants with 3 species: Cannabis Sativa Cannabis Indica Cannabis Ruderalis Plant
More informationOnfi (clobazam) Labeled Uses: Clobazam is used as adjuvant treatment of seizures from Lennox-Gastaut Syndrome. 1,2
Onfi (clobazam) Brand Name: Onfi Generic Name: clobazam Manufacturer: Lundbeck Inc. Drug Class: Benzodiazepine Labeled Uses: Clobazam is used as adjuvant treatment of seizures from Lennox-Gastaut Syndrome.
More informationEpidiolex in Dravet Syndrome and Lennox- Gestaut Syndrome (LGS) 27 September 2018 Presented by: Giuliana Campo 2019 PharmD Candidate 1
Epidiolex in Dravet Syndrome and Lennox- Gestaut Syndrome (LGS) 27 September 2018 Presented by: Giuliana Campo 2019 PharmD Candidate 1 Objectives To understand the epidemiology and pathophysiology of LGS
More informationMedicinal Marijuana: The Canadian Journey
Medicinal Marijuana: The Canadian Journey Nady el-guebaly MD Professor & Head, Addiction Division, UofC Research Director, Alberta Gambling Research Institute Chief Examiner, ISAM Certification Disclosures:
More informationGW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy
December 7, 2015 GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy As previously announced, seven posters
More informationNorthern California Chapter, ACP Update In Medicine
Northern California Chapter, ACP Update In Medicine Kathleen A. Kenny MD Clinical Associate Professor of Medicine Primary Care and Population Health November 3, 2018 UPDATE ON MARIJUANA Kathleen A. Kenny
More informationMARIJUANA & THE EFFECTS ON THE BRAIN
MARIJUANA & THE EFFECTS ON THE BRAIN Sheryl Ryan, MD Professor of Pediatrics Chief, Division of Adolescent Medicine, Penn State Health Hershey Medical Center DISCLOSURES I have no relevant financial relationships
More informationWHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis. Expert Peer Review 2
WHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis Expert Peer Review 2 1. Comments based on the review report a. Evidence on dependence and abuse potential Extracts
More informationCannabis: Rocky Mountain Highlights for Health Care Providers
Cannabis: Rocky Mountain Highlights for Health Care Providers HASHing It Out: Overview of Medical Uses for Marijuana Skaggs School of Pharmacy Webinar Series Laura Borgelt, PharmD, FCCP, BCPS Associate
More informationMedical Marijuana Myths and Realities
Medical Marijuana Myths and Realities Herbert D. Kleber, M.D. Professor of Psychiatry Director, Division on Substance Abuse Columbia University/NYSPI October 8, 2013 THS 2013 Biarritz Introduction Marijuana
More informationFrom Opioid Replacement to Managing Chronic Pain: What is CBD?
From Opioid Replacement to Managing Chronic Pain: What is CBD? Kalev Freeman, MD PhD Assistant Professor of Surgery and Pharmacology, University of Vermont Laura Mann Integrative Healthcare Lecture Series
More informationSusan Allen-Evenson Hosts: Laura Lagano, MS, RDN, CDN Prepare for the Next Level: Incorporating Holistic Cannabis in the Nutrition Practice
Susan Allen-Evenson Hosts: Laura Lagano, MS, RDN, CDN Prepare for the Next Level: Incorporating Holistic Cannabis in the Nutrition Practice Integrative Clinical Nutritionist, Laura Lagano MS, RDN, CDN
More informationCBD Oil: Benefits, Top Products, Where To Buy, And More
CBD Oil: Benefits, Top Products, Where To Buy, And More CBD hemp oil has a huge range of potential health benefits and uses, including reducing pain, soothing anxiety, fighting cancer, improving mood,
More informationCannabis in the Community
Department of Pediatrics Cannabis in the Community The Unintended Consequences of Increased Marijuana Availability on the Pediatric Population Karen Buchi, MD Professor of Pediatrics Chair, University
More informationOXZGEN FAQ s What is the Endocannabinoid System? What are cannabinoids? What is CBD oil?
OXZGEN FAQ s What is the Endocannabinoid System? Discovered only a few decades ago, the endocannabinoid system (ECS) is one of the most important physiological systems in our body. It consists of a group
More informationObjectives. 1. Review controversy 2. Pathophysiology 3. Indications for Use 4. Adverse Effects 5. How Patients Access
Medical Marijuana Deb Evans, RN, MScN, CON(C), CHPCN(C) Clinical Nurse Specialist Pain and Symptom Management Team Juravinski Cancer Centre May 29, 2014 Objectives 1. Review controversy 2. Pathophysiology
More informationGlobal Legal Cannabis Market: Size, Trends & Forecasts ( ) September 2018
Global Legal Cannabis Market: Size, Trends & Forecasts (2018-2022) September 2018 Global Legal Cannabis Market: Coverage Executive Summary and Scope Introduction/Market Overview Global Market Analysis
More informationMarijuana and the Chronic Non-Cancer Pain Patient
Marijuana and the Chronic Non-Cancer Pain Patient Kevin P. Hill, M.D., M.H.S. Pain 101: Provider Workshop 9/23/16 McLean Hospital Division of Alcohol and Drug Abuse khill@mclean.harvard.edu DrKevinHill.com,
More informationThe Scientific Side of Medical Marijuana
The Scientific Side of Medical Marijuana Ken Mackie, MD Indiana University Bloomington, IN December 3, 2009 kmackie@indiana.edu Financial disclosures NIH (NIDA) - research grants Alzheimer s Association
More informationCannabis for Medical Use: Body and Mind
Cannabis for Medical Use: Body and Mind Shaul Schreiber, MD Division of Psychiatry, Tel Aviv Sourasky Medical Center; Tel Aviv University Sackler Faculty of Medicine; Sagol School of Neuroscience, Israel
More informationCoalition for Medical Marijuana Research & Education
Coalition for Medical Marijuana Research & Education Nagi Kumar, Ph.D., R.D., FADA Professor, Oncologic Sciences Director, Cancer Chemoprevention Executive Director, Coalition for Medical Marijuana Research
More informationDrug Class Update with New Drug Evaluations: Antiepileptics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationINTRODUCTION WHAT IS MARIJUANA 2/28/2018
INTRODUCTION AT THE END OF THE SESSION, YOU WILL ASSESS THE USE AND IMPACT (SIDE EFFECTS) OF MARIJUANA ON PATIENTS EXPLORE CANNABIS THERAPY LEGALITY AND PRACTICALITY POSSESS STRATEGIES TO PROVIDE PSYCHO-EDUCATIONAL
More informationUse of Cannabinoids in Medical Practice
Use of Cannabinoids in Medical Practice Annual Scientific Assembly Family Medicine Review 2016 Murray Opdahl BSPE, MD, CCFP Objectives Briefly present: An overview of available cannabinoids Concerns voiced
More informationMARIJUANA in MEDICAL CARE READY or RISKY. HINDI MERMELSTEIN, MD FAPM Beth Israel Medical Center, NYC Dec
MARIJUANA in MEDICAL CARE READY or RISKY HINDI MERMELSTEIN, MD FAPM drhmermelstein @optimum.net Beth Israel Medical Center, NYC Dec 11 2015 HISTORY MARIJUANA (CANNABIS SAVITA) HAS LONG BEEN PART OF RELIGIOUS
More informationCannabis Use: Scope of the Issue
Three Areas of Focus How Changing Cannabis Policy Will Affect Your Practice Kevin P. Hill, MD, MHS Director, McLean Hospital Division of Alcohol and Drug Abuse Belmont, MA Assistant Professor of Psychiatry,
More informationMedicinal Cannabis. Patient Log Book. Record your cannabis use and find the right dose
Medicinal Cannabis Patient Log Book Record your cannabis use and find the right dose 1 Introduction A federal system is in place for medicinal cannabis that is distinct from recreational sales. To get
More informationJuly 15 TH, ANDREW MEDVEDOVSKY, M.D. Board Certified Neurologist & Pain Medicine Specialist Director New Jersey Alternative Medicine
MEDICAL CANNABIS FOR NEUROLOGICAL DISEASES July 15 TH, 2017 ANDREW MEDVEDOVSKY, M.D. Board Certified Neurologist & Pain Medicine Specialist Director New Jersey Alternative Medicine GOALS AND OBJECTIVES
More informationThis is a duplicated text of a letter from GW Pharma Ltd. Contact the company for a copy of any references, attachments or enclosures.
Health Canada posts safety alerts, public health advisories, press releases and other notices from industry as a service to health professionals, consumers and other interested parties. Although Health
More informationMedical Cannabis. Danial Schecter, MD, CCFP. Vocational Rehabilitation Association November 7th, Executive Director Cannabinoid Medical Clinic
Medical Cannabis Danial Schecter, MD, CCFP Executive Director Cannabinoid Medical Clinic Vocational Rehabilitation Association November 7th, 2014 Conflict of Interest This program has not received financial
More informationMarijuana as Medicine
Marijuana as Medicine What is medical marijuana? The term medical marijuana refers to using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions.
More informationEpilepsy Medications: The Basics
Epilepsy Medications: The Basics B R I A N A P P A V U, M D C L I N I C A L A S S I S T A N T P R O F E S S O R, D E P A R T M E N T O F C H I L D H E A L T H A N D N E U R O L O G Y, U N I V E R S I T
More informationMedical Marijuana for Pain How Does Cannabis Work on Your Body?
Medical Marijuana for Pain How Does Cannabis Work on Your Body? Jeremy Spiegel, MD Medical Director - Casco Bay Medical Westbury, Long Island, New York Intro Brief History of Cannabis Physiology of Cannabis
More informationCDHA 2016 Fall Symposium. Speaker Handout Files. For registered attendees only
CDHA 2016 Fall Symposium Speaker Handout Files For registered attendees only Providing Care in a Marijuana Legal World Heather Rogers, BSDH heatherrdh@heatherrdh.com Objectives We will discuss some of
More informationMEDICAL CANNABIS PATIENT COUNSELING. Krissy Bernazani, RPh Clinical Director Zen Leaf
MEDICAL CANNABIS PATIENT COUNSELING Krissy Bernazani, RPh Clinical Director Zen Leaf DISCLOSURE Krissy Bernazani is a paid employee of Freestate Wellness, dba Zen Leaf Maryland, a medical cannabis dispensary.
More informationMedical Cannabis: A Patient Primer
Medical Cannabis: A Patient Primer This primer is meant for documented patients who are using medicinal cannabis or considering using it in the future. The information provided about this medication in
More informationMedical Marijuana A Primer for Pharmacists
Medical Marijuana A Primer for Pharmacists Emory S. Martin, PharmD FASHP Texas Society of Health System Pharmacists Learning Objectives Recognize key components of the endocannabinoid system Identify possible
More informationGetting Into the Weed: Potentials and Pitfalls Affecting Medical Use
Getting Into the Weed: Potentials and Pitfalls Affecting Medical Use Cydney E. McQueen, PharmD Clinical Associate Professor UMKC School of Pharmacy Objectives Describe in simple terms the endocannabinoid
More informationCannabis and the Endocannabinoid System
Cannabis and the Endocannabinoid System September 7, 2018 Bangkok, Thailand David Bearman, MD Goleta, California Executive VP, American Academy of Cannabinoid Medicine AACMSITE.org Shen Nung Ping
More informationMedical Cannabis. Christine Yoshioka, NP
Medical Cannabis Christine Yoshioka, NP Objectives Brief history of Cannabis in cultures Review of the Endocanabinoid system Exogenous cannabis Medical research involving cannabis and federal restrictions
More informationLegalized Marijuana: Uses, Misuses & Abuses. Disclosures. Objectives. Kennon Heard University of Colorado SOM Dept Of Emergency Medicine
Legalized Marijuana: Uses, Misuses & Abuses Kennon Heard University of Colorado SOM Dept Of Emergency Medicine Disclosures Research grants McNeil Consumer Healthcare (Acetaminophen) Rare Disease Therapeutics
More informationHEALTH WELLNESS COMMUNITY
HEALTH WELLNESS COMMUNITY As with all modern medicines, our understanding of cannabis and its benefits has deepened over time thanks to groundbreaking advancements in research and technology. At Trilogy
More informationADVERSE EVENTS OF NEW AEDS. LIONEL CARMANT, MD Professor of Neurosciences and Pediatrics
ADVERSE EVENTS OF NEW AEDS LIONEL CARMANT, MD Professor of Neurosciences and Pediatrics DISCLOSURE Lionel Carmant: Grants/Research projects: Mettrum/ Zogenix Speakers bureau: UCB, Eisai, Lina Nova Off
More information